Pirtobrutinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50mg, 100mg
Reference Brands: Jaypirca(USA/EU)
Category:
Oncology Cancer Care
Pirtobrutinib is a highly selective, non-covalent BTK inhibitor designed to overcome resistance to earlier BTK inhibitors. It is used in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. By reversibly inhibiting BTK, it blocks signaling required for cancer cell survival and proliferation.
Pirtobrutinib is available in Tablets
and strengths such as 50mg, 100mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pirtobrutinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pirtobrutinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing